Umoja Biopharma
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1150 Eastlake Ave E Ste 400, Seattle, Wa...Website
www.umoja-biopharma.comRevenue
$40.2 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
4
1
1
2
2
About Umoja Biopharma
Umoja Biopharma, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja's novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. Designed from the ground up to work together, these platforms are being developed to create and harness a powerful immune response in the body to directly, safely, and controllably attack cancer. Umoja believes that its approach can provide broader access to the most advanced immunotherapies and enable more patients to live better, fuller lives.Explore more
Umoja Biopharma Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Umoja Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Umoja Biopharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if Umoja Biopharma had a recent Job posting/layoffs
Product Launch: Get notified when Umoja Biopharma launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Umoja Biopharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Umoja Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Umoja Biopharma recently announced quarterly report
Check out if Umoja Biopharma is spiking on competitors!
Funding: Get notified immidiatlly once Umoja Biopharma has new funding data
Recommended Actions
Find VP level buyers at Umoja Biopharma
Find more new buyers
Compare Similar Companies to Umoja Biopharma
Compare insights from companies similar to Umoja Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Umoja Biopharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Umoja Biopharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Umoja Biopharma.
Umoja Biopharma financials insights
Gather financial insights about Umoja Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$53M
2021
Series B
$210M
2025
Series C
$100M
Umoja Biopharma Tech Stack
A closer look at the technologies used by Umoja Biopharma
See more technologies
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
Umoja Biopharma has more open roles in Engineering & Technical than it has had at any time in the past 12 months. Technologies mentioned include: R. Areas of expertise include: Requirements Specifications, Process Management, Smartsheet, Bioreactors, Process Analytical Technology, Process Specification, and Project Management.
Hiring Plans
Open Position
Open Position
Umoja Biopharma News & Media
Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting
- Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma -Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
SEATTLE, March 23, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and autoimmune diseases, today announced the appointment of Marcela Maus, M.D., Ph.D., and Athena Countouriotis, M.D., to its Board of Directors. Drs. Maus and Countouriotis bring deep expertise spanning cellular immunotherapy research, clinical development, and biotechnology companyNona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, Mass., Nov. 5, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I™), today announced an evaluation and license agreement with Umoja Biopharma ("Umoja"), the clinical-stage leader of in vivo cell...Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, Mass., Nov. 5, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I™), today announced an evaluation and license agreement with Umoja Biopharma ("Umoja"), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR-T cells. This agreement represents an expansion of the strategic collaboration established between the two companies in September 2024. The expanded part
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Umoja Biopharma
Sign Up For FreeTo access detailed company insights
Umoja Biopharma, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja's novel approach is powered by integrated cellular immunotherapy technologies... Read More
